The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The AICVD tool can predict the risk of cardiovascular disease.
People in India are still wary of organ transplants. So, there is an urgent need of increased public awareness.
Medicines, including insulin, to be available in 40 lower-income countries
Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
It is a two dose vaccine to be administered intramuscularly at 28 days apart
Subscribe To Our Newsletter & Stay Updated
